최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기자원환경지질 = Economic and environmental geology, v.48 no.3, 2015년, pp.241 - 246
Helicobacter pylori is an important transmissible human pathogen found on the luminal surface of the gastric epithelium. The organism can persist in the stomach indefinitely and causes gastroduodenal inflammation that may proceed to atrophic gastritis, peptic ulcer, gastric MALT lymphoma, and gastri...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
세계적 성인 H. pylori 감염률은 어떻게 되는가? | 전 세계적으로 H. pylori 감염률은 성인에서 약 50% 정도이며, 개발도상국이나 저개발국에서 높고, 성별, 연령, 지역 분포, 종족 간에도 차이를 보인다(World Gastroenterology Organisation, 2011). 미국이나 유럽과 같은 선진국에서의 H. | |
Helicobacter pylori가 장기간 기생하면 어떤 질환을 일으키는가? | Helicobacter pylori는 사람의 위점막에서 발견되는 전염성이 있는 중요한 병원균이다. 장기간 기생하면서 만성위염, 소화성궤양, 위 변연부 B세포 림프종, 그리고 위암을 일으키는 세균으로 알려져 있다. 국내에서는 프로톤펌프 억제제(proton pump inhibitor, PPI)와 두 가지 항생제(amoxicillin, clarithromycin)를 포함하는 표준 삼제 요법을 1차 치료로 사용하여 왔으나, 점점 증가하고 있는 항생제 내성으로 인해 제균율은 점차 감소하고 있다. | |
Helicobacter pylori란 무엇인가? | Helicobacter pylori는 그람음성 막대균으로 1983년 Warren과 Marshall에 의해 처음으로 사람의 위점막 표면에 서식하는 세균으로 발견되었다(Warren and Marshall, 1983). 이후 여러 연구에서 사람의 위점막에 장기간 기생하면서 만성위염을 일으킬 뿐만 아니라, 감염자의 1-10%에서 소화성궤양, 0. |
al-Moagel, M.A., Evans, D.G., Abdulghani, M.E., Adam, E., Evans, D.J.Jr., Malaty, H.M. and Graham, D.Y. (1990) Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. American Journal of Gastroenterology, v.85, p.944-948.
Basu, P.P., Rayapudi, K., Pacana, T., Shah, N.J., Krishnaswamy, N. and Flynn, M. (2011) A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. American Journal of Gastroenterology, v.106, p.1970-1975.
Brenciaglia, M.I., Fornara, A.M., Scaltrito, M.M., Braga, P.C. and Dubini, F. (1996) Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Journal of Chemotherapy, v.8, p.52-54.
Gasbarrini, A., Franceschi, F., Armuzzi, A., Ojetti, V., Candelli, M., Torre, E.S., De Lorenzo, A., Anti, M., Pretolani, S. and Gasbarrini, G. (1999) Extradigestive manifestations of Helicobacter pylori gastric infection. Gut, v.45 p.I9-I12.
Irie, Y., Tateda, K., Matsumoto, T., Miyazaki, S. and Yamaguchi, K. (1997) Antibiotic MICs and short timekilling against Helicobacter pylori: therapeutic potential of kanamycin. Journal of Antimicrobial Chemotherapy, v.40, p.235-240.
Kim, J.D. and Kang, Y.G. (2012), 2012 National Health Insurance Statistical Yearbook, National Health Insurance Corporation, Health Insurance Review & Assessment Service.
Kim, J.M., Kim, J.S., Jung, H.C., Kim, N., Kim, Y.J., and Song, I.S. (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrobial Agents and Chemotherapy, v.48, p.4843-4847.
Kim, S.G., Jung, H.K., and Lee, H.L. (2013) Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean Journal of Gastroenterology, v.13, n.62, p.3-26.
Klein, P.D., Graham, D.Y., Gaillour, A., Opekun, A.R. and Smith, E.O. (1991) Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. The Lancet, v.337, p.1503-1506.
Lee, J.W., Kim, N., Kim, J.M., Nam, R. H., Chang, H., Kim, J.Y., Shin, C.M., Park, Y.S., Lee, D.H. and Jung, H.C. (2013) Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter, v.18, p.206-214.
Lee, J.Y. and Kim, N.Y. (2014) Future trends of Helicobacter pylori eradication therapy in Korea. Korean Journal of Gastroenterology, v.14, n.63, p.158-170.
Lee, J.Y., Kim, N., Kim, M.S., Choi, Y.J., Lee, J.W., Yoon, H., Shin, C.M., Park, Y.S., Lee, D.H. and Jung, H.C. (2014) Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Digestive Diseases and Sciences, v.59, n.6, p.1235-1243.
Li, Z., Chang, P.H., Jean, J.S., Jiang, W.T. and Wang, C.J. (2010) Interaction between tetracycline and smectite in aqueous solution. Journal of Colloid and Interface Science, v.341, p.311-319.
NIH Consensus Conference. (1994) H. pylori in peptic ulcer disease. NIH Consensus development panel on Helicobacter pylori in peptic ulcer disease. Journal of the American Medical Association, v.272, p.65-69.
Nishizawa, T., Suzuki, H., Suzuki, M., Takahashi, M. and Hibi, T. (2012) Proton pump inhibitor-amoxicillinclarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. Journal of Clinical Biochemistry and Nutrition, v.51, p.114-116.
Oh, H.S., Lee, D.H., Seo, J.Y., Cho, Y.R., Kim, N., Hwang, J.H., Park, Y.S., Lee, S.H., Shin, C.M., Cho, H.J., Jung, H.C. and Song, I.S. (2012) Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. Journal of Gastroenterology and Hepatology, v.27, p.504-509.
Park, C.S., Lee, S.M., Park, C.H., Koh, H.R., Jun, C.H., Park, S.Y., Lee, W.S., Joo, Y.E., Kim, H.S., Choi, S.K. and Rew, J.S. (2014) Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. American Journal of Gastroenterology, v.109, p.1595-1602.
Rimbara, E., Fischbach, L.A. and Graham, D.Y. (2011) Optimal therapy for Helicobacter pylori infections. Nature Reviews Gastroenterology and Hepatology, v.8, p.79-88.
Shiota, S., Murakawi, K., Suzuki, R., Fujioka, T. and Yamaoka, Y. (2013) Helicobacter pylori infection in Japan. Expert Review of Gastroenterology and Hepatology, v.7 p.35-40.
Suerbaum, S. and Michetti, P. (2002) Helicobacter pylori infection, New England. Journal of Medicine, v.347, p.1175-1186
van der Voort, P.H.J., van der Hulst, R.W.M., Zandstra, D.F., van der Ende, A., Geraedts, A.A.M. and Tytgat, G.N.J. (2000) In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract. Journal of Antimicrobial Chemotherapy, v.46, p.803-805.
Warren, J.R. and Marshall, B.J. (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. The Lancet, v.321, n.8336, p.1273-1275.
World Gastroenterology Organisation global guideline. (2011): Helicobacter pylori in developing countries. Journal of Digestive Diseases, v.12, p.319-326.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.